Adaptive Biotechnologies (ADPT)
(Real Time Quote from BATS)
$4.11 USD
+0.07 (1.73%)
Updated Jul 22, 2024 03:22 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Adaptive Biotechnologies Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 170 | 185 | 154 | 98 | 85 |
Cost Of Goods | 76 | 58 | 49 | 23 | 22 |
Gross Profit | 95 | 127 | 105 | 76 | 63 |
Selling & Adminstrative & Depr. & Amort Expenses | 322 | 328 | 314 | 229 | 141 |
Income After Depreciation & Amortization | -227 | -200 | -209 | -153 | -78 |
Non-Operating Income | 16 | 4 | 2 | 7 | 10 |
Interest Expense | 14 | 4 | 0 | 0 | 0 |
Pretax Income | -225 | -200 | -207 | -146 | -69 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -225 | -200 | -207 | -146 | -69 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -225 | -200 | -207 | -146 | -69 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -214 | -179 | -188 | -144 | -75 |
Depreciation & Amortization (Cash Flow) | 13 | 22 | 21 | 9 | 3 |
Income After Depreciation & Amortization | -227 | -200 | -209 | -153 | -78 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 144.38 | 142.52 | 140.36 | 131.22 | 69.17 |
Diluted EPS Before Non-Recurring Items | -1.38 | -1.40 | -1.48 | -1.11 | -1.01 |
Diluted Net EPS (GAAP) | -1.56 | -1.40 | -1.48 | -1.11 | -1.01 |
Fiscal Year end for Adaptive Biotechnologies Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 41.87 | 45.78 | 37.92 | 48.93 |
Cost Of Goods | NA | 18.05 | 19.62 | 19.35 | 17.91 |
Gross Profit | NA | 23.82 | 26.17 | 18.57 | 31.02 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 72.59 | 97.24 | 69.53 | 78.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -48.77 | -71.07 | -50.96 | -47.81 |
Non-Operating Income | NA | 4.22 | 4.61 | 4.28 | 3.61 |
Interest Expense | NA | 2.99 | 3.01 | 3.65 | 3.61 |
Pretax Income | NA | -47.53 | -69.47 | -50.33 | -47.81 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.03 | -0.03 | -0.03 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -47.53 | -69.47 | -50.33 | -47.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -47.51 | -69.44 | -50.30 | -47.81 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 145.79 | 144.90 | 144.71 | 144.40 |
Diluted EPS Before Non-Recurring Items | NA | -0.33 | -0.30 | -0.35 | -0.33 |
Diluted Net EPS (GAAP) | NA | -0.33 | -0.48 | -0.35 | -0.33 |